β-(1-adamantyl)-α,α-dimethylethylamine hydrochloride | 68693-30-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: β-(1-adamantyl)-α,α-dimethylethylamine hydrochloride
• 英文别名: beta-(1-adamantyl)-alpha,alpha-dimethylethylamine hydrochloride；1-(1-adamantyl)-2-methylpropan-2-amine;hydron;chloride
• CAS: 68693-30-1
• 化学式: C₁₄H₂₅N*ClH
• 分子量: 243.82
• InChiKey: UKYQQGVXUPSJCX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.75
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  N-formyl-β-(1-adamantyl)-α,α-dimethylethylamine 在 盐酸 作用下， 以 正己烷 为溶剂， 生成 β-(1-adamantyl)-α,α-dimethylethylamine hydrochloride
  参考文献：
  名称：

  Anorectic adamantane derivatives and method of using the same

  摘要：

  金刚烷衍生物，如β-(1-金刚烷基)-α,α-二甲基乙胺盐酸盐、β-(1-金刚烷基)-α-甲基乙胺盐酸盐、d-β-(1-金刚烷基)-α-甲基乙胺盐酸盐和1-β-(1-金刚烷基)-α-甲基乙胺盐酸盐具有压食活性。上述化合物的肼衍生物是降压剂和单胺氧化酶抑制剂。

  公开号：

  US04100170A1

文献信息

• [EN] TRICYCLIC INHIBITORS OF INFLUENZA VIRUS ENDONUCLEASE<br/>[FR] INHIBITEURS TRICYCLIQUES DE L'ENDONUCLÉASE DU VIRUS DE LA GRIPPE
  申请人：WEBB THOMAS R

  公开号：WO2021195278A1

  公开（公告）日：2021-09-30

  The present disclosure is concerned with 9-hydroxy-6-(pyrrolidin-2-yl)-3,4-dihydro-2H-pyrazino[ 1,2-c]pyrimidine- 1, 8-dione compounds for the treatment of various viral infections such as, for example, influenza virus. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  本公开涉及用于治疗各种病毒感染的9-羟基-6-(吡咯啉-2-基)-3,4-二氢-2H-吡嗪并[1,2-c]嘧啶-1,8-二酮化合物，例如流感病毒。本摘要旨在作为在特定领域搜索的扫描工具，并不意在限制本发明。
• [EN] PRODRUG COMPOSITIONS AND METHODS OF TREATMENT<br/>[FR] COMPOSITIONS DE PROMÉDICAMENT ET PROCÉDÉS DE TRAITEMENT
  申请人：AQUESTIVE THERAPEUTICS INC

  公开号：WO2021087359A1

  公开（公告）日：2021-05-06

  Pharmaceutical compositions include a prodrug of epinephrine are described.

  药物组合物包括表述的肾上腺素前药。
• Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
  申请人：Rogers D. Robin

  公开号：US20070093462A1

  公开（公告）日：2007-04-26

  Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.

  揭示了离子液体及制备活性药物、生物、营养和能量成分的离子液体组合物的方法。还揭示了利用本文描述的组合物的方法，以克服多型性、克服溶解度和输送问题、控制释放速率、增加功能性、增强功效（协同作用）以及改善易用性和制造工艺。
• [EN] MITOCHONDRIAL ALDEHYDE DEHYDROGENASE 2 (ALDH2) BINDING POLYCYCLIC AMIDES AND THEIR USE FOR THE TREATMENT OF CANCER<br/>[FR] AMIDES POLYCYCLIQUES SE LIANT À L'ALDÉHYDE DÉSHYDROGÉNASE 2 (ALDH2) MITOCHONDRIALE ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER
  申请人：ALDEA PHARMACEUTICALS INC

  公开号：WO2015127137A1

  公开（公告）日：2015-08-27

  The present invention provides compounds of formula I that bind to mitochondrial aldehyde dehydrogenase-2 (ALDH2), and methods of using said compounds to treat patients with i.a. cancer, Fanconi anemia and alcohol-related disorders. [Formula should be inserted here] wherein i.a. A is O or NH; RA is H, cycloalkyl or alkyl optionally substituted with a carbocycle; X1 and X2 are N or CH; R1, R2, R3 and R4 are H; and Z is an optionally substituted 5- or 6-membered aromatic ring.

  本发明提供了化合物I的公式，该化合物与线粒体醛脱氢酶-2（ALDH2）结合，并且使用这些化合物的方法来治疗患有癌症、范可尼贫血和与酒精相关疾病的患者。其中i.a. A为O或NH；RA为H，环烷基或烷基，可选地用碳环取代；X1和X2为N或CH；R1、R2、R3和R4为H；Z为一个可选取代的5-或6-成员芳香环。
• OPHTHALMIC COMPOSITIONS COMPRISING dDC
  申请人：Hughes Patrick M.

  公开号：US20100056547A1

  公开（公告）日：2010-03-04

  A composition comprising dDC and a polymer, wherein the composition is an aqueous liquid with a viscosity which increases upon contact with a surface of an eye is disclosed herein. An aqueous composition comprising a therapeutically effective concentration of dDC, wherein the concentration of dDC is less than 1% is also disclosed. An eye drop comprising a therapeutically effective amount of dDC, wherein the amount of dDC is less than 300 μg is also disclosed. A method comprising administering an effective amount of dDC topically to an eye of a person suffering from viral conjunctivitis a viral infection, wherein less than 300 μL of dDC is administered to said eye is also disclosed. A kit comprising a composition and a dispenser, wherein said dispenser dispenses a drop comprising a therapeutically effective amount of dDC, wherein the amount of dDC is less than 300 μg is also disclosed.

  本文披露了一种包含dDC和聚合物的组合物，其中该组合物是一种水性液体，其粘度在接触眼睛表面时会增加。还披露了一种包含治疗有效浓度的dDC的水性组合物，其中dDC的浓度小于1%。还披露了一种眼用滴剂，其中含有治疗有效量的dDC，其中dDC的量小于300微克。还披露了一种方法，包括向患有病毒性结膜炎的人的眼部局部给予有效量的dDC，其中向该眼部给予的dDC少于300微升。还披露了一种包括组合物和分配器的套件，其中该分配器分配含有治疗有效量的dDC的滴剂，其中dDC的量小于300微克。